|
1
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baba Y, Saeki H, Nakashima Y, Oki E,
Shigaki H, Yoshida N, Watanabe M, Maehara Y and Baba H: Review of
chemotherapeutic approaches for operable and inoperable esophageal
squamous cell carcinoma. Dis Esophagus. 30:1–7. 2017.
|
|
3
|
Tamaki Y, Hieda Y, Nakajima M, Kitajima K,
Yoshida R, Yoshizako T, Ue A, Tokudo M, Hirahara N, Moriyama I, et
al: Concurrent chemoradiotherapy with docetaxel, cisplatin, and
5-fluorouracil improves survival of patients with advanced
esophageal cancer compared with conventional concurrent
chemoradiotherapy with cisplatin and 5-fluorouracil. J Cancer.
9:2765–2772. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fokas E, Weiss C and Rodel C: The role of
radiotherapy in the multimodal management of esophageal cancer. Diq
Dis. 31:30–37. 2013. View Article : Google Scholar
|
|
5
|
Wang Q, Zhu H, Xiao Z, Zhang W, Liu X,
Zhang X, He J, Sun K, Wang L and Xu N: Expression of epidermal
growth factor receptor is an independent prognostic factor for
esophageal squamous cell carcinoma. World J Surg Oncol. 11:2782013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abdo J, Agrawal DK and Mittal SK: Basis
for molecular diagnostics and immunotherapy for esophageal cancer.
Expert Rev Anticancer Ther. 17:33–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hong L, Han Y and Brain L: Epidermal
growth factor receptor: An important target in esophageal cancer.
Expert Opin Ther Targets. 17:1179–1185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sasada T, Azuma K, Ohtake J and Fujimoto
Y: Immune responses to epidermal growth factor receptor (EGFR) and
their application for cancer treatment. Front Pharmacol. 7:4052016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cohen RB: Current challenges and clinical
investigations of epidermal growth factor receptor (EGFR)- and ErbB
family-targeted agents in the treatment of head and neck squamous
cell carcinoma (HNSCC). Cancer Treat Rev. 40:567–577. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chi A, Remick S and Tse W: EGFR inhibition
in non-small cell lung cancer: Current evidence and future
directions. Biomark Res. 1:22013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen EE, Rosen F, Stadler WM, Recant W,
Stenson K, Huo D and Vokes EE: Phase II trial of ZD1839 in
recurrent or metastatic squamous cell carcimoma of the head and
neck. J Clin Oncol. 21:1980–1987. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan CM, Ma BB, Wong SC and Chan AT:
Celecoxib induces dose dependent growth inhibition in nasopharygeal
carcinoma cell lines independent of cyclooxygenase-2 expression.
Biomed Phamacother. 59:S268–S271. 2005. View Article : Google Scholar
|
|
13
|
Provencio M and Sánchez A: Therapeutic
integration of new molecule-targeted therapies with radiotherapy in
lung cancer. Transl Lung Cancer Res. 3:89–94. 2014.PubMed/NCBI
|
|
14
|
Chinnaiyan P, Huang S, Vallabhaneni G,
Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM and Harari PM:
Mechanisms of enhanced radiation response following epidermal
growth factor receptor signaling inhibition by erlotinib (Tarceva).
Cancer Res. 65:3328–3335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ku GY and Ilson DH: Emerging tyrosine
kinase inhibitors for esophageal cancer. Expert Opin Emerg Drugs.
18:219–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu M, Wang X, Shen L, Jia J, Gong J, Li J,
Li J, Li Y, Zhang X, Lu Z, et al: Nimotuzumab plus paclitaxel and
cisplatin as the first line treatment for advanced esophageal
squamous cell cancer: A single centre prospective phase II trial.
Cancer Sci. 107:486–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Diaz-Miqueli A and Martinez GS:
Nimotuzumab as a radiosensitizing agent in the treatment of high
grade glioma: Challenges and opportunities. Onco Targets Ther.
6:931–942. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang T, Min W, Li Y, Yue Z, Wu C and Zhou
C: Radiotherapy plus EGFR TKIs in non-small cell lung cancer
patients with brain metastases: An update meta-analysis. Cancer
Med. 5:1055–1065. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye F, Chen C, Qin J, Liu J and Zheng C:
Genetic profiling reveals an alarming rate of cross-contamination
among human cell lines used in China. FASEB J. 29:4268–4272. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Crombet T, Osorio M, Cruz T, Roca C, del
Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J,
Renginfo E, et al: Use of the humanized anti-epidermal growth
factor receptor monoclonal antibody h-R3 in combination with
radiotherapy in the treatment of locally advanced head and neck
cancer patients. J Clin Oncol. 22:1646–1654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mukhopadhyay C, Zhao X, Maroni D, Band V
and Naramura M: Distinct effects of EGFR ligands on human mammary
epithelial cell differentiation. PLoS One. 8:e759072013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang
W, Di W and Qiu L: MicroRNA-7 inhibits tumor metastasis and
reverses epithelial-mesenchymal transition through AKT/ERK1/2
inactivation by targeting EGFR in epithelial ovarian cancer. PLoS
One. 9:e967182014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Andrade SS, Sumikawa JT, Castro ED,
Batista FP, Paredes-Gamero E, Oliveira LC, Guerra IM, Peres GB,
Cavalheiro RP, Juliano L, et al: Interface between breast cancer
cells and the tumor microenvironment using platelet-rich plasma to
promote tumor angiogenesis-influence of platelets and fibrin
bundles on the behavior of breast tumor cells. Oncotarget.
8:16851–16874. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Navarini D, Gurski RR, Madalosso CA, Aita
L, Meurer L and Fornari F: Epidermal growth factor receptor
expression in esophageal adenocarcinoma: Relationship with tumor
stage and survival after esophagectomy. Gastroenterol Res Pract.
2012:9419542012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szabó B, Nelhubel GA, Kárpáti A, Kenessey
I, Jóri B, Székely C, Peták I, Lotz G, Hegedus Z, Hegedus B, et al:
Clinical significance of genetic alterations and expression of
epidermal growth factor receptor (EGFR) in head and neck squamous
cell carcinomas. Oral Oncol. 47:487–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ,
Kim YJ, Kim JH, Kang E, Kim SW, Kim IA and Park SY: High EGFR gene
copy number predicts poor outcome in triple-negative breast cancer.
Mod Pathol. 27:1212–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ayyappan S, Prabhakar D and Sharma N:
Epidermal growth factor receptor (EGFR)-targeted therapies in
esophagogastric cancer. Anticancer Res. 33:4139–4155.
2013.PubMed/NCBI
|
|
28
|
Wang Y, Pan L, Sheng XF, Chen S and Dai
JZ: Nimotuzumab, a humanized monoclonal antibody specific for the
EGFR, in combination with temozolomide and radiation therapy for
newly diagnosed glioblastoma multiforme: First results in Chinese
patients. Asia Pac J Clin Oncol. 12:e23–e29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nitta Y, Shimizu S, Shishido-Hara Y,
Suzuki K, Shiokawa Y and Nagane M: Nimotuzumab enhances
temozolomide-induced growth suppression of glioma cells expressing
mutant EGFR in vivo. Cancer Med. 5:486–499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chong DQ, Toh XY, Ho IA, Sia KC, Newman
JP, Yulyana Y, Ng WH, Lai SH, Ho MM, Dinesh N, et al: Combined
treatment of Nimotuzumab and rapamycin is effective against
temozolomide-resistant human gliomas regardless of the EGFR
mutation status. BMC Cancer. 15:2552015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boland WK and Bebb G: Nimotuzumab: A novel
anti-EGFR monoclonal antibody that retains anti-EGFR activity while
minimizing skin toxicity. Expert Opin Biol Ther. 9:1199–1206. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gridelli C, Maione P, Ferrara ML and Rossi
A: Cetuximab and other anti-epidermal growth factor receptor
monoclonal antibodies in the treatment of non-small cell lung
cancer. Oncologist. 14:601–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Basavaraj C, Sierra P, Shivu J, Melarkode
R, Montero E and Nair P: Nimotuzumab with chemoradiation confers a
survival advantage in treatment-naïve head and neck tumors over
expressing EGFR. Cancer Biol Ther. 10:673–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ramos-Suzarte M, Lorenzo-Luaces P, Lazo
NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ,
Moreno BP, Alvarez ES, et al: Treatment of malignant,
non-resectable, epithelial origin esophageal tumours with the
humanized anti-epidermal growth factor antibody nimotuzumab
combined with radiation therapy and chemotherapy. Cancer Biol Ther.
13:600–605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baumann M, Krause M, Dikomey E, Dittmann
K, Dörr W, Kasten-Pisula U and Rodemann HP: EGFR-targeted
anti-cancer drugs in radiotherapy: Preclinical evaluation of
mechanisms. Radiother Oncol. 83:238–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shaltiel IA, Krenning L, Bruinsma W and
Medema RH: The same, only different -DNA damage checkpoints and
their reversal throughout the cell cycle. J Cell Sci. 128:607–620.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fan QW and Weiss WA: RNA interference
against a glioma-derived allele of EGFR induces blockade at G2M.
Oncogene. 24:829–837. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin S, Yan Y, Liu Y, Gao CZ, Shan D, Li Y
and Han B: Sensitisation of human lung adenocarcinoma A549 cells to
radiotherapy by Nimotuzumab is associated with enhanced apoptosis
and cell cycle arrest in the G2/M phase. Cell Biol Int. 39:146–151.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Garrido G, Tikhomirov IA, Rabasa A, Yang
E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS and Pérez
R: Bivalent binding by intermediate affinity of nimotuzumab: A
contribution to explain antibody clinical profile. Cancer Biol
Ther. 11:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao L, He LR, Xi M, Cai MY, Shen JX, Li
QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, et al: Nimotuzumab promotes
radiosensitivity of EGFR-overexpression esophageal squamous cell
carcinoma cells by upregulating IGFBP-3. J Transl Med. 10:2492012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Akashi Y, Okamoto I, Iwasa T, Yoshida T,
Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K and
Nakagawa K: Enhancement of the antitumor activity of ionising
radiation by nimotuzumab, a humanised monoclonal antibody to the
epidermal growth factor receptor, in non-small cell lung cancer
cell lines of differing epidermal growth factor receptor status. Br
J Cancer. 98:749–755. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu H, Yang W, Gao H, Jiang T, Gu B, Dong
Q, Xu W, Wu S and Sun X: Nimotuzumab abrogates acquired
radioresistance of KYSE-150R esophageal cancer cells by inhibiting
EGFR signaling and cellular DNA repair. Onco Targets Ther.
8:509–518. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Berger C, Krengel U, Stang E, Moreno E and
Madshus IH: Nimotuzumab and cetuximab block ligand-independent egf
receptor signaling efficiently at different concentrations. J
Immunother. 34:550–555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang X, Ji Y, Kang X, Chen M, Kou W, Jin C
and Lu P: Study on chemotherapeutic sensitizing effect of
nimotuzumab on different human esophageal squamous carcinoma cells.
Oncol Lett. 11:973–978. 2016. View Article : Google Scholar : PubMed/NCBI
|
